Table of Contents
ALBANY, N.Y. and MILWAUKEE — GE Healthcare has entered into a global licensing pact with medical testing product specialist Bionime Corp. to provide new GE-branded solutions for the diabetes market.
 |
The GE100 Blood Glucose Monitoring System is the lead-off product in the GE-Bionime partnership. |
The General Electric Co. health care unit said Tuesday that under the agreement, Bionime will deliver GE-branded blood glucose monitors, test strips, kits and related diabetes accessories.
According to the companies, the first product being launched is the GE100 Blood Glucose Monitoring System, available now through durable medical equipment suppliers and being rolled out on retail shelves in 2012.
"We are very excited to work with Bionime to provide innovative blood glucose monitoring for diabetes patients worldwide," commented David Ataide, general manager for strategic and customer initiatives at GE Healthcare. "Managing diabetes care is critical to the health of our society, and we believe this an important first step for our business."
The GE100 uses advanced, patented strip technology to achieve a high level of accuracy and precision, and its innovative strip design makes it easier to use and more sanitary for the consumer than current similar offerings, GE and Bionime said.
In addition, patented True Auto Coding Technology eliminates the need to code each strip lot without sacrificing the accuracy of the readings, the companies added.
"Bionime’s vision is that with our ‘peace of mind’ medical devices, we offer solutions to patients to accurately manage and control their own health," stated Roy Huang, chairman of Bionime. "By joining forces with GE, we can grow this vision by developing new offerings and widening the market for Bionime’s products."
